

## Director/PDMR Shareholding

June 1, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”)

### Notification of transactions by person discharging managerial responsibilities

<b>1.</b>	<b>Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated them (“PCA”)</b>		
a)	Name	Kim Stratton	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position / status	Head of International Commercial - PDMR	
b)	Initial notification / amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Shire plc	
b)	LEI	54930005LQRLI2UXRQ59	
<b>4.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	Shire plc Ordinary Shares of 5 pence each (“Ordinary Shares”)	
	Identification code	ISIN: JE00B2QKY057	
b)	Nature of the transaction	Receipt of Ordinary Shares following the vesting of Restricted Stock Units (“RSUs”) awarded under the Shire Long Term Incentive Plan 2015 on June 1, 2015.  (Details of related disposal of Ordinary Shares are referenced in section 5. below.)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		N/A	15
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)	
e)	Date of the transaction	June 1, 2017	
f)	Place of the transaction	N/A	
<b>5.</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where</b>		

<b>transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")  ISIN: JE00B2QKY057
b)	Nature of the transaction	Automated disposal of Ordinary Shares in relation to the vesting of RSUs referenced in section 4. above. The proceeds of this disposal were used to satisfy personal tax liabilities arising from the vesting of the RSUs.
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		£44.7780
		5
d)	Aggregated information - Aggregated volume - Price	N/A (single transaction)
e)	Date of the transaction	June 1, 2017
f)	Place of the transaction	London Stock Exchange

Oliver Strawbridge  
Senior Assistant Company Secretary

**For further information please contact:**

**Investor Relations**

Ian Karp [ikarp@shire.com](mailto:ikarp@shire.com) +1 781 482 9018  
Robert Coates [rcoates@shire.com](mailto:rcoates@shire.com) +44 1256 894874

**Media**

Lisa Adler [lisa.adler@shire.com](mailto:lisa.adler@shire.com) +1 617 588 8607  
Debbi Ford [debbi.ford@shire.com](mailto:debbi.ford@shire.com) +1 617 949 9083

**NOTES TO EDITORS**

**About Shire**

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

[www.shire.com](http://www.shire.com)